πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 837 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 8771696

Method of reducing the severity of stress hyperglycemia with human antibodies to the gluca

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jul 08 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 03 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8765125

Methods of treating autoimmune diseases with Dll4 antagonists

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jul 01 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 26 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8735095

High affinity human antibodies to human IL-4 receptor

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue May 27 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 22 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8710004

Stable liquid VEGF antagonist formulations

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Apr 29 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 24 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8692052

Genetically modified mice and engraftment

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Apr 08 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 03 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8658853

Low affinity FcΞ³R deficient mice

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Feb 25 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 20 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8658154

Humanized FcΞ³R mice

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Feb 25 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 20 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8647842

Methods for producing a fusion protein capable of binding VEGF

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Feb 11 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 06 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8642741

Human antibodies to human TNF-like ligand 1A (TL1A)

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Feb 04 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 30 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8637031

Method of treating osteoarthritis with an antibody to NGF

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jan 28 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 23 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8613927

High affinity human antibodies to human nerve growth factor

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Dec 24 2013 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 19 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8597898

Fusion polypeptides capable of activating receptors

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Dec 03 2013 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8586713

Readily isolated bispecific antibodies with native immunoglobulin format

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Nov 19 2013 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 14 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8568721

Method of treating rheumatoid arthritis with an anti-IL-6R antibody

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Oct 29 2013 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 24 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8545847

Human antibodies to the human glucagon receptor and methods of use thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Oct 01 2013 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 26 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8541646

Genetically modified mice and engraftment

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Sep 24 2013 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 19 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8518887

Method of treating cancer with DLL4 antagonist and chemotherapeutic agent

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Aug 27 2013 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 22 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8501184

High affinity human antibodies to PCSK9

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Aug 06 2013 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 01 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8481046

VEGF antagonist formulations for intravitreal administration

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jul 09 2013 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 04 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8470324

Fusion polypeptides capable of activating receptors

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jun 25 2013 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 20 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8445434

IGF-1 fusion polypeptides and therapeutic uses thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue May 21 2013 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 16 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8425907

Methods for treating pruritus by administering an antibody that specifically binds human P

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Apr 23 2013 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 18 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8414876

Methods of using IL-1 antagonists to treat autoinflammatory disease

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Apr 09 2013 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 04 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8414890

Human antibodies to human RANKL, encoding nucleic acids and methods of treatment

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Apr 09 2013 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 04 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted